share_log

Ladenburg Thalmann Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $2

Ladenburg Thalmann Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $2

拉登堡·塔爾曼以買入評級啓動對Alterity Therapeutics的報道,宣佈目標股價爲2美元
Benzinga Real-time News ·  2022/08/03 07:10

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $2.

拉登堡·塔爾曼分析師Aydin Huseynov以買入評級啟動對Alterity治療公司(納斯達克:Athe)的報道,並宣佈目標價為2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論